neratinib
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Jul 9, 2009 → Oct 4, 2019
NCT ID
NCT00878709About neratinib
neratinib is a phase 3 stage product being developed by Puma Biotechnology for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00878709. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05919108 | Phase 2 | Recruiting |
| NCT04781374 | Phase 2 | Withdrawn |
| NCT03812393 | Phase 2 | UNKNOWN |
| NCT00878709 | Phase 3 | Completed |
| NCT00864487 | Phase 1 | Completed |
| NCT00814060 | Phase 1 | Completed |
| NCT00757809 | Phase 1 | Completed |
| NCT00550212 | Phase 1 | Completed |
| NCT00498745 | Phase 1 | Completed |
| NCT00397046 | Phase 1 | Completed |
| NCT00380328 | Phase 1 | Completed |
| NCT00300781 | Phase 2 | Completed |
| NCT00366600 | Phase 1 | Completed |
| NCT00146172 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer